Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Missed radiologic disease activity by conventional side-by-side MRI comparison is associated with future disease activity in multiple sclerosis: Adopting semiautomated coregistration-fusion into clinical practice.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Cerebellar magnetization transfer ratio and its relationship to clinical outcomes in radiologically isolated syndrome and multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Gestational Exposure to 10 Classes of Priority Chemicals and Birth Outcomes in the ECHO Cohort.

JAMA network open·2026
Same author

Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.

The Lancet. Neurology·2026
Same author

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.

Neurology·2026
Same author

Prenatal exposure to organophosphate ester flame retardants and plasticizers and maternal immune responses in three ECHO cohorts.

Environmental research·2026
Same journal

Characterizing Onset Limit and Surgical Outcome Factors in Type II Focal Cortical Dysplasia-Related Epilepsy.

Neurology. Clinical practice·2026
Same journal

Efficacy and Safety of Perampanel in Patients With Brain Tumor-Related Epilepsy: A Systematic Review and Meta-Analysis.

Neurology. Clinical practice·2026
Same journal

Patient-Reported Symptom Burden in Individuals With Parkinson Disease.

Neurology. Clinical practice·2026
Same journal

Global Access to Diagnostic Paraclinical Testing Incorporated in the 2024 Revised McDonald Criteria: Disparities and Opportunity.

Neurology. Clinical practice·2026
Same journal

Clinical Differentiation of Self-Limited Epilepsy With Autonomic Seizures (Panayiotopoulos Syndrome) and Childhood Migraine.

Neurology. Clinical practice·2026
Same journal

The National Association of Epilepsy Centers Accreditation Criteria Should Include Care for People With Functional/Dissociative Seizures.

Neurology. Clinical practice·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Teriflunomide.

Jiwon Oh1, Paul W O'Connor

  • 1Department of Neurology (JO), Johns Hopkins University, Baltimore, MD; and Division of Neurology, Department of Medicine (JO, PWO), St. Michael's Hospital, University of Toronto, Toronto, Canada.

Neurology. Clinical Practice
|August 6, 2013
PubMed
Summary
This summary is machine-generated.

Teriflunomide offers an effective and safe oral treatment option for multiple sclerosis (MS). Clinical trials confirm its efficacy, adding a valuable new therapy to the MS treatment landscape.

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Experiment Videos

Last Updated: May 9, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Current MS treatments include injectables and infusions, with a need for oral alternatives.
  • Teriflunomide represents a new oral disease-modifying therapy for MS management.

Purpose of the Study:

  • To review the pharmacology of teriflunomide.
  • To summarize pivotal clinical trial data on teriflunomide's efficacy and safety.
  • To discuss teriflunomide's place among current and emerging MS treatments.

Main Methods:

  • Review of published literature on teriflunomide and leflunomide.
  • Analysis of data from large, multicenter, phase III clinical trials of teriflunomide.
  • Synthesis of safety and efficacy findings.

Main Results:

  • Teriflunomide demonstrated clinical efficacy in phase III trials for multiple sclerosis.
  • The drug was found to have an acceptable safety profile.
  • Oral administration offers a convenient treatment option for MS patients.

Conclusions:

  • Teriflunomide is a valuable new oral treatment for multiple sclerosis.
  • Its efficacy and safety profile support its use in MS management.
  • Teriflunomide expands therapeutic options for patients with multiple sclerosis.